Buizza Giulia, Paganelli Chiara, Ballati Francesco, Sacco Simone, Preda Lorenzo, Iannalfi Alberto, Alexander Daniel C, Baroni Guido, Palombo Marco
Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milan, 20133, Italy.
Diagnostic Radiology Residency School, University of Pavia, Pavia, 27100, Italy.
Med Phys. 2021 Mar;48(3):1250-1261. doi: 10.1002/mp.14689. Epub 2021 Feb 5.
Proton therapy could benefit from noninvasively gaining tumor microstructure information, at both planning and monitoring stages. The anatomical location of brain tumors, such as meningiomas, often hinders the recovery of such information from histopathology, and conventional noninvasive imaging biomarkers, like the apparent diffusion coefficient (ADC) from diffusion-weighted MRI (DW-MRI), are nonspecific. The aim of this study was to retrieve discriminative microstructural markers from conventional ADC for meningiomas treated with proton therapy. These markers were employed for tumor grading and tumor response assessment.
DW-MRIs from patients affected by meningioma and enrolled in proton therapy were collected before (n = 35) and 3 months after (n = 25) treatment. For the latter group, the risk of an adverse outcome was inferred by their clinical history. Using Monte Carlo methods, DW-MRI signals were simulated from packings of synthetic cells built with well-defined geometrical and diffusion properties. Patients' ADC was modeled as a weighted sum of selected simulated signals. The weights that best described a patient's ADC were determined through an optimization procedure and used to estimate a set of markers of tumor microstructure: diffusion coefficient (D), volume fraction (vf), and radius (R). Apparent cellularity (ρ ) was estimated from vf and R for an easier clinical interpretability. Differences between meningothelial and atypical subtypes, and low- and high-grade meningiomas were assessed with nonparametric statistical tests, whereas sensitivity and specificity with ROC analyses. Similar analyses were performed for patients showing low or high risk of an adverse outcome to preliminary evaluate response to treatment.
Significant (P < 0.05) differences in median ADC, D, vf, R, and ρ values were found when comparing meningiomas' subtypes and grades. ROC analyses showed that estimated microstructural parameters reached higher specificity than ADC for subtyping (0.93 for D and vf vs 0.80 for ADC) and grading (0.75 for R vs 0.67 for ADC). High- and low-risk patients showed significant differences in ADC and microstructural parameters. The skewness of ρ was the parameter with highest AUC (0.90) and sensitivity (0.75).
Matching measured with simulated ADC yielded a set of potential imaging markers for meningiomas grading and response monitoring in proton therapy, showing higher specificity than conventional ADC. These markers can provide discriminative information about spatial patterns of tumor microstructure implying important advantages for patient-specific proton therapy workflows.
在质子治疗的计划和监测阶段,非侵入性地获取肿瘤微观结构信息可能会使质子治疗受益。脑肿瘤(如脑膜瘤)的解剖位置常常妨碍从组织病理学中获取此类信息,而传统的非侵入性成像生物标志物,如扩散加权磁共振成像(DW-MRI)中的表观扩散系数(ADC),并不具有特异性。本研究的目的是从接受质子治疗的脑膜瘤患者的传统ADC中提取具有鉴别性的微观结构标志物。这些标志物用于肿瘤分级和肿瘤反应评估。
收集了接受质子治疗的脑膜瘤患者治疗前(n = 35)和治疗后3个月(n = 25)的DW-MRI图像。对于后一组患者,根据其临床病史推断不良结局的风险。使用蒙特卡罗方法,从具有明确几何和扩散特性的合成细胞堆积中模拟DW-MRI信号。将患者的ADC建模为所选模拟信号的加权和。通过优化程序确定最能描述患者ADC的权重,并用于估计一组肿瘤微观结构标志物:扩散系数(D)、体积分数(vf)和半径(R)。为了便于临床解释,根据vf和R估计表观细胞密度(ρ)。采用非参数统计检验评估脑膜内皮型和非典型亚型以及低级别和高级别脑膜瘤之间的差异,通过ROC分析评估敏感性和特异性。对显示不良结局低风险或高风险的患者进行类似分析,以初步评估治疗反应。
在比较脑膜瘤的亚型和级别时,发现中位数ADC、D、vf、R和ρ值存在显著(P < 0.05)差异。ROC分析表明,估计的微观结构参数在亚型分类(D和vf的特异性为0.93,ADC为0.80)和分级(R的特异性为0.75,ADC为0.67)方面比ADC具有更高的特异性。高风险和低风险患者在ADC和微观结构参数方面存在显著差异。ρ的偏度是AUC最高(0.90)和敏感性最高(0.75)的参数。
将测量的ADC与模拟的ADC相匹配,产生了一组用于质子治疗中脑膜瘤分级和反应监测的潜在成像标志物,其特异性高于传统ADC。这些标志物可以提供有关肿瘤微观结构空间模式的鉴别信息,这对个体化质子治疗工作流程具有重要优势。